Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast
The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes already on the market for type 2 diabetes (e.g., SGLT-2 inhibitors), but a few early-phase agents (e.g., VX-880) offer a novel mechanism of action. The emphasis has shifted on the types of therapies in development for T1D; interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors is significant. The availability of biosimilar insulins is also likely to have a sizable effect on the T1D therapy market throughout the G7, resulting in an intricate interplay of physician and payer attitudes toward this treatment option.
QUESTIONS ANSWERED
- What are the drivers and constraints in the T1D market, and how will the market evolve over the forecast period?
- How are biosimilar insulins being adopted in the markets under study?
- What impact will the increasing use of insulin pumps have on market dynamics?
- How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the most clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
- How will ultra-rapid insulins, such as Novo Nordisk’s Fiasp and Eli Lilly’s Lyumjev, be incorporated into treatment in the major markets?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of T1D by country with population-specific diagnosed and drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key T1D therapies through 2031, segmented by brands / generics and epidemiological subpopulations.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select preclinical, Phase I, and Phase II products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Type 1 diabetes key findings - July 2022
- Key updates
- Q4 2022
- December 2022
- November 2022
- October 2022
- Q3 2022
- September 2022
- August 2022
- Q2 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for type 1 diabetes: 2021
- Market share of drug classes for type 1 diabetes: 2031
- Type 1 diabetes SWOT analysis
- Market drivers and constraints
- What factors are driving the market for type 1 diabetes?
- What factors are constraining the market for type 1 diabetes?
- Market sales of type 1 diabetes drug classes in the major markets: 2021-2031
- Patient share of type 1 diabetes drug classes in the major markets: 2021-2031
- Drug-class specific trends
- Long-acting insulins
- Patient share of long-acting insulins in type 1 diabetes in the United States: 2021-2031
- Patient share of long-acting insulins in type 1 diabetes in Europe: 2021-2031
- Patient share of long-acting insulins in type 1 diabetes in Japan: 2021-2031
- Rapid-acting insulins
- Patient share of rapid-acting insulins in type 1 diabetes in the United States: 2021-2031
- Patient share of rapid-acting insulins in type 1 diabetes in Europe: 2021-2031
- Patient share of rapid-acting insulins in type 1 diabetes in Japan: 2021-2031
- Ultra-rapid-acting insulins
- Patient share of ultra-rapid-acting insulins in type 1 diabetes in major markets: 2021-2031
- Other insulins
- Patient share of other insulins in type 1 diabetes in major markets: 2021-2031
- Patient share of SGLT inhibitors in type 1 diabetes in major markets: 2021-2031
- Patient share of immunotherapy in type 1 diabetes (newly-diagnosed patients) in major markets: 2021-2031
- Market sales of immunotherapy in type 1 diabetes (newly-diagnosed patients) in major markets: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Risk factors for type 1 diabetes
- Pathophysiology
- Type 1 diabetes: how the disease might arise
- Natural history
- Key pathways and drug targets
- Summary of type 1 diabetes drug targets
- Disease overview
- Epidemiology overview
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed prevalence estimates of type 1 diabetes
- Diagnosed prevalent cases of type 1 diabetes: 2021-2031 (thousands)
- Drug-treated prevalent cases of type 1 diabetes: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for type 1 diabetes
- Key current therapies
- Overview
- Mechanism of action of key current drugs used for type 1 diabetes
- Current treatments used for type 1 diabetes
- Advantages and disadvantages of Glargine U100
- Advantages and disadvantages of detemir
- Advantages and disadvantages of degludec
- Advantages and disadvantages of glargine U300
- Expert insight: long-acting insulins
- Advantages and disadvantages of aspart
- Advantages and disadvantages of glulisine
- Advantages and disadvantages of lispro
- Advantages and disadvantages of technosphere
- Ongoing clinical development of technosphere
- Expert insight: rapid-acting insulins
- Advantages and disadvantages of ultra-rapid aspart
- Advantages and disadvantages of ultra-rapid lispro
- Expert insight: ultra-rapid-acting insulins
- Advantages and disadvantages of premixed insulins
- Expert insight: premixed insulins
- Advantages and disadvantages of regular insulin
- Advantages and disadvantages of NPH insulin
- Expert insight: short- and intermediate-acting insulins
- Advantages and disadvantages of dapagliflozin
- Advantages and disadvantages of ipragliflozin
- Expert insight: SGLT inhibitors
- Advantages and disadvantages of pramlintide
- Medical practice
- Overview
- Factors influencing drug selection in type 1 diabetes
- Generalized treatment decision tree for type 1 diabetes: major markets
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in type 1 diabetes
- Top unmet needs in type 1 diabetes: current and future attainment
- Expert insight: unmet need in type 1 diabetes
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for type 1 diabetes
- Estimated launch dates of key emerging therapies for the treatment of type 1 diabetes
- Teplizumab profile
- Key ongoing clinical trials of teplizumab for the treatment of type 1 diabetes
- Analysis of the clinical development program for teplizumab
- Expectations for launch and sales opportunity of teplizumab in type 1 diabetes
- Expert insight: teplizumab
- Key results from select clinical trials investigating ladarixin for the treatment of type 1 diabetes
- Key ongoing clinical trials of ladarixin for the treatment of type 1 diabetes
- Analysis of the clinical development program for ladarixin
- Expectations for launch and sales opportunity of ladarixin in type 1 diabetes
- Key results from select clinical trials investigating Diamyd for the treatment of type 1 diabetes
- Key ongoing clinical trials of Diamyd for the treatment of type 1 diabetes
- Analysis of the clinical development program for Diamyd
- Expectations for launch and sales opportunity of Diamyd in type 1 diabetes
- Key ongoing clinical trials of insulin icodec for the treatment of type 1 diabetes
- Analysis of the clinical development program for insulin icodec
- Expectations for launch and sales opportunity of insulin icodec in type 1 diabetes
- Key ongoing clinical trials of LY3209590 for the treatment of type 1 diabetes
- Analysis of the clinical development program for LY3209590
- Expectations for launch and sales opportunity of LY3209590 in type 1 diabetes
- Sotagliflozin profile
- Analysis of the clinical development program for sotagliflozin
- Expectations for launch and sales opportunity of sotagliflozin in type 1 diabetes
- Early-phase pipeline analysis
- Select compounds in Phase II development for type 1 diabetes
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in type 1 diabetes: United States
- General reimbursement environment: United States
- Key market access considerations in type 1 diabetes: EU5
- General reimbursement environment: EU5
- Key market access considerations in type 1 diabetes: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Type 1 diabetes bibliography
- Key findings
Shambhavi Shukla, M.Tech., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Ms. Shukla has authored competitive landscape and market insight reports on type 1 and type 2 diabetes, osteoporosis, and FSGS. Before joining Clarivate, she was with Evalueserve, where she worked closely with top pharmaceutical companies, helping them with commercial and technical ad-hoc requests. She holds a master’s degree in biotechnology from Amity University in India.